Vantage Health Technologies extends its collaboration with the Medicines for Malaria Venture for another three years
Vantage Health Technologies is pleased to announce a new collaboration with MMV (Medicines for Malaria Venture) over the next three years.
‘MMV’s mission aligns to our own as they strive to reduce the burden of malaria in disease endemic countries by discovering, developing, and delivering, effective and affordable antimalarial drugs,’ explains Paul Bhuhi, Managing Director of Vantage Health Technologies. ‘This will be implemented through our Data Lab solution which will provide crucial analytic support through our Vantage platform, helping MMV to distributed malaria prophylaxis to 19 million children each year’.
MMV is one of BroadReach Group’s longest active customers with the relationship extending over six years. Their vote of confidence shows that they recognize the value Vantage has brought to them over the past three years where the platform has been used throughout their childhood malaria programs within the Sahel region in Africa.
The program will support MMV to realise the following business outcomes:
- Reducing current manual workload to free up resources to focus on critical issues
- Empowering the Access & Product Management team to easily access the information and answers they need in a few clicks, without the need to involve analytics experts
- Providing critical information on a self-service’s basis to key internal and external stakeholders
- Enabling MMV to manage the process with minimal dependence upon a 3rd party vendor.
‘The new program gives us another opportunity to showcase our values: calling us to be bold, enterprising, collaborative and our word,’ explains Chris Le Grand, BroadReach Group CEO. ’It brings us one step closer to our mission, where access to good health enables people to flourish.’